Background-Glucagon-like peptide-1 (GLP-1) (7-36) amide is an intestinal incretin hormone which also inhibits gastric acid secretion in humans. Its mechanism of action is unclear, but it strongly inhibits vagaily induced secretion (sham feeding), suggesting that it could influence vagal activity. Aim/Methods-The effect of intravenous GLP-1 (7-36 amide) (1 pmollkg/min) was studied on pentagastrin induced acid secretion in otherwise healthy subjects, previously vagotomised for duodenal ulcer (n=8) and in a group of young (n=8) and old (n=6) healthy volunteers. Results-Pentagastrin increased acid secretion significantly in all three groups, but the plateau concentration in the vagotomised subjects was lower than in controls. Infusion of GLP-1 (7-36 amide) significantly inhibited acid secretion in the control groups (to 67 (SEM 6) and 74 (SEM 3)% of plateau concentrations in young and old controls, respectively) but had no effect in the vagotomised subjects. Differences in plasma concentrations of GLP-1 (7-36 amide), recovery of gastric marker, duodenal regurgitation, or Helicobacter pylorn status could not explain the lack of effect. Blood glucose was lowered equally by GLP-1 (7-36 amide) in all subjects. Conclusion-The inhibitory effect of GLP-1 (7-36 amide) on acid secretion depends on intact vagal innervation of the stomach. (Gut 1997; 40: 597-601) Keywords: ileal brake, enterogastrone, vagotomy, pentagastrin, proglucagon.
Glucagon-like peptide-1 (GLP-1) (7-36 amide) is a peptide processed from proglucagon in open type endocrine cells (L cells) in the small intestine and colon,'-5 from which it is released into the circulation in response to feeding.3 9 It has attracted considerable interest because of its potent insulinotropic and glucagonostatic effects, whereby it lowers blood glucose. Because of this it has been proposed as a therapeutic agent in the treatment of type 2 diabetes mellitus.1l-5 In addition to its glucoregulatory effects GLP-1 (7-36 amide) strongly inhibits gastrointestinal motility and secretion including meal and pentagastrin stimulated acid secretion.'1'8 It has, therefore, been suggested to act as an important enterogastrone in humans."" '5 It is not clear by what mechanism(s) GLP-1 (7-36 amide) inhibits acid secretion in humans. Conceivably, it might act locally by inhibiting parietal cell secretion directly or indirectly via a paracrine action of an increased release of somatostatin. It might also act by inhibiting vagal transmission to the parietal cells at the gastric level or by inhibiting vagal efferent activity via a central mechanism. Recent experiments in our laboratory have shown that GLP-1 (7-36 amide) in physiological concentrations almost abolished acid secretion induced by sham feeding, indicating that GLP-1 (7-36 amide) effectively also inhibits neurally induced acid secretion.19
To determine whether the inhibitory effect of GLP-1 (7-36 amide) on acid secretion is exerted at the gastric level or whether it involves mainly neural mechanisms we have investigated its effects on pentagastrin induced acid secretion in patients previously treated for duodenal ulcer disease by selective vagotomy.
Methods

SUBJECTS
Two women and six men, mean age 67 (SEM 3) years, who were operated on for an uncomplicated duodenal ulcer in the period 1964-71 were studied. All had had a selective vagotomy and pyloroplasty a.m. HeinekeMikulicz. The vagotomy was considered complete in all patients as evidenced by more than 90% reduction in insulin induced peak acid output three months and five years after the operation. Since the operation none of the subjects has had a history of recurrent ulcer disease or signs of gastric outlet obstruction. Because of the age of the vagotomised subjects, two groups of control subjects were also investigated. One consisted of three women and five men, mean age 23 (SEM 1) years, the other comprised five men and one women, mean age 61 (SEM 2) years. All subjects were investigated for infection with Helicobacter pylori using a serological method. 
RADIOIMMUNOASSAYS
Human GLP-1 (7-36 amide) was measured using synthetic GLP-1 (7-36 amide) as a standard (Peninsula), '25I-labelled GLP-1 (7-36 amide), and antiserum 89390. 7 The antibody has an absolute requirement for the amidated C-terminus of the molecule for binding. Blood glucose was determined by the hexokinase method.22 STATISTICAL 
ANALYSIS
All results are presented as means (SEM). The mean acid output in the basal period (0-30 minutes), the two last 15 minute periods during pentagastrin stimulation alone (60-90 minutes), during GLP-1 (7-36 amide) infusion (120-150 minutes), and after GLP-1 (7-36 amide) infusion (180-210 minutes) were used for statistical analysis. The significance between groups was evaluated by analysis of variance (ANOVA) followed by Newman-Keul's multiple range test; p<005 was considered significant.
Results
The recovery of the gastric marker averaged 99 (2)% in the young controls, 100 (4)% in the age matched controls, and 96 (3)% in the patients (not significantly different). Osmolarity (Table I) increased slightly in all subjects as a consequence of the pentagastrin infusion, but there were no significant differences between the groups and no effect of the GLP-1 (7-36 amide) infusion, indicating that differences in duodenogastric reflux did not influence the results. Figures 1 and 2 show the acid secretion. In the controls acid secretion increased from 1 1 (0 3) mEq/15 min in the basal state to 4 8 (0 5) mEq/15 min in the young group and from 1 2 (0 3) mEq/15 min to 6-2 (1-5) mEq/15 min in the old group during infusion of pentagastrin. The GLP-1 (7-36 amide) infusion significantly decreased acid secretion to 3-3 (0 5) mEq/15 min and 4-6 (1 1) mEq/15 min respectively. After termination of the GLP-1 (7-36 amide) infusion, acid secretion returned to preinfusion concentrations (5 0 (0 6) mEq/1 5 min and 5 9 (1 2) mEq/1 5 min). In the patients basal acid secretion averaged 0-1 (0 05) mEq/15 min. Pentagastrin increased acid secretion to 1-9 (0'4) mEq/15 min, but GLP-1 (7-36 amide) had no effect on this stimulated rate of secretion (1) (2) (3) (4) (5) (6) (7) (8) GLP-1 (7-36 amide) infusion and 1-8 (0-4) mEq during the last 60 minutes). Figure 3 shows that GLP-1 (7-36 amide) infusion increased plasma concentrations of GLP-1 (7-36 amide) from 5 (1) pmol/l to a plateau of 42 (6) pmol/l and 58 (6) pmol/l in the young and old control groups, respectively, and from 7 (1) pmol/l to 72 (6) pmol/ in the patients. There was no significant difference between the plateaux in the patients and the old controls. The GLP-1 (7-36 amide) infusion significantly and equally effectively decreased blood glucose concentrations in all groups (Table II) .
Six out of eight vagotomised subjects were H pylori positive, whereas one out of the six old controls and one out of the eight young controls were positive. In both of the two positive control subjects GLP-1 (7- '6 17 and in the old controls acid secretion decreased to 74 (3)% of plateau values, excluding that the lack of inhibition in the older vagotomised subjects was a consequence of age. Besides, the blood glucose lowering effect of GLP-1 (7-36 amide), which is thought to reflect a direct effect of GLP-1 (7-36 amide) on the pancreatic islet cells,'3 was similar in all three groups. In a recent study, Olbe et al3 found that the inhibition of gastric acid elicited by antral distension was lost in patients infected with Hpylori. Six out of our eight vagotomised patients were H pylori positive, but the remaining two, as in the others, failed to show inhibition of acid secretion with GLP-1 (7-36 amide). Furthermore, in both of the two positive controls GLP-1 (7-36 amide) was fully effective. A H pylori infection, therefore, is not likely as an explanation of the lack of effect of GLP-1 (7-36 amide) after vagotomy. Hypothetically, vagotomised subjects might be less sensitive to GLP-1 (7-36 amide) than normal subjects. However, we used an infusion rate that in normal subjects is maximally or near maximally effective.24 In addition, despite identical rates of infusion in all groups, the GLP-1 (7-36 amide) concentrations obtained in the vagotomised subjects tended to be higher than in the old controls and were significantly higher than in the young controls. Thus we find it unlikely that an inadequate 
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